Biogen (BIIB) PT Lowered to $338 at Credit Suisse
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.92 -2.09%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 20
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 20
Join SI Premium – FREE
Credit Suisse analyst Evan Seigerman lowered the price target on Biogen (NASDAQ: BIIB) to $338.00 (from $350.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Hesai (2525:HK) (HSAI) PT Lowered to HK$24.20 at Macquarie
- Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
